NCT07397819 2026-02-09Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard TherapySun Yat-sen UniversityPhase 1/2 Recruiting48 enrolled